Cordlife Group Limited · SGX:P8A
Cordlife — FY2021 Earnings Presentation
20 slides from Cordlife's earnings presentation, 2022
Slide 1: FY2021 Results Presentation
FY2021 Results Presentation
Slide 2: Disclaimer
Disclaimer This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Cordlife Group Limited (“Cordlife”) in Singapore or any other jurisdiction nor shall it or any part of it form the basi
Slide 3: Content
Content 1 Overview 2 Financial Highlights 3 Outlook & Growth Strategies 4 Financial Highlights 3
Slide 4: Overview
Overview 4
Slide 5: Business Overview – Operating Segments
Business Overview – Operating Segments BANKING CORD LINING MESENCHYMAL DIAGNOSTICS CORD BLOOD CORD LINING STEM CELLS DIGITAL HEALTHCARE OTHERS CORD LINING CORD TISSUE CORD TISSUE EPITHELIAL MESENCHYMAL STEM CELLS STEM CELLS
Slide 6: Business Overview – Operating Segments
Business Overview – Operating Segments PREIMPLANTATION NON-INVASIVE NEWBORN BANKING ENDOMETRIAL GENETIC RECEPTIVITY PRENATAL METABOLIC DIAGNOSTICS SCREENING TESTING SCREENING DIGITAL HEALTHCARE TEST MOMS UP OTHERS NEWBORN GENETIC LIFE SPROUTS GENETIC PAEDIATRIC PAEDIATRIC TALENT TEST SCREENING VISIO
Slide 7: Business Overview – Market Presence
Business Overview – Market Presence BANKING DIAGNOSTICS DIGITAL HEALTHCARE OTHERS Our Network Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singap
Slide 8: Financial Highlights
Financial Highlights 8
Slide 9: FY2021 Results Summary
FY2021 Results Summary REVENUE GROSS PROFIT GP MARGIN S$56.7 million S$39.5 million 69.7% (3.9)% y-o-y (1.6)% y-o-y +1.7 pp y-o-y NET PROFIT NET PROFIT MARGIN NET CASH1 S$6.1 million 10.8% S$79.0 million (6.3)% y-o-y (0.3)pp y-o-y +S$7.8m from 31 Dec 2020 1: Includes cash and cash equivalents, fixed
Slide 10: 2H2021 Results Summary
2H2021 Results Summary REVENUE GROSS PROFIT GP MARGIN S$29.4 million S$20.7 million 70.5% 3.3% y-o-y 7.1% y-o-y +2.5 pp y-o-y NET PROFIT NET PROFIT MARGIN S$3.6 million 12.4% (7.1)% y-o-y (1.4)pp y-o-y 10
Slide 11: Financials – Revenue
Financials – Revenue S$ mil 80.0 69.5 70.0 60.0 59.0 59.0 56.7 40.0 20.0 — FY2017 12M2018 FY2019 FY2020 FY2021 – The Group’s FY2021 revenue decreased 3.9% year-on-year to S$56.7 million. – This was due to lower new samples processed and stored as a result of ongoing COVID-19 pandemic. – However, thi
Slide 12: Financials – Quarter-on-quarter Revenue
Financials – Quarter-on-quarter Revenue S$ mil 20.0 17.7 18.0 17.8 16.5 16.6 15.0 14.6 14.8 14.6 14.0 13.9 13.9 13.4 10.0 5.0 — 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 2Q2020 3Q2020 4Q2020 1Q2021 2Q2021 3Q2021 4Q2021 – The Group’s 4Q2021 revenue demonstrated resilience at S$14.6 million. – This was due t
Slide 13: Financials – Gross Profit
Financials – Gross Profit S$ mil 90 68.7% 68.0% 69.7% 66.8% 64.2% 80 70 60 50 46.5 48.1 37.8 40.1 39.5 40 30 20 10 0 FY2017 12M2018 FY2019 FY2020 FY2021 Gross profit Gross profit Margin 13
Slide 14: Financials – Operating profit after tax
Financials – Operating profit after tax 10 S$ mil 9 10.2% 9.7% 8.4% 8 0.9% 1.7% 7 5.8 6.0 6 5.5 5 4 3 2 1.2 1 0.5 0 FY2017 12M2018 FY2019 FY2020 FY2021 Operating profit after tax Net operating profit margin 14
Slide 15: Financials – Balance Sheet
Financials – Balance Sheet S$’ mil As at 31 Dec 2021 As at 31 Dec 2020 Net Assets 136.7 133.2 Borrowings — 4.0 Gearing1 (%) — 3.0 Cash & Cash Equivalents, Fixed Deposits, Short-term and Long-term 79.0 75.2 Investments Net Asset Value Per Share (SG cents) 53.54 52.33 1: Total Borrowings/Total Equity
Slide 16: Financials – Cash Flow
Financials – Cash Flow For the year ended For the year ended S$’ mil 31 Dec 2021 31 Dec 2020 Net cash generated from operating activities 9.5 15.9 Net cash generated from investing activities (14.2) (1.3) Net cash used in financing activities (6.3) (2.9) Cash & cash equivalents at end of the 15.5 25
Slide 17: Outlook & Growth Strategies
Outlook & Growth Strategies 17
Slide 18: Outlook
Outlook Business Outlook – The Group managed to achieve stability in revenue over the past quarters by adapting quickly and pivoting with the evolving landscape. – The COVID-19 situation has generally resulted in the tapering of new customer sign-ups for banking services, but this may improve as the
Slide 19: Growth Strategies
Growth Strategies Increase penetration jor market share Increase product scope Organic Open new markets Growth Facilitate development of stem cell Create new engines of growth ic with current Mergers& Acquisitions Eamings accretive Targeting Asia
Slide 20: Thank you
Thank you 20